HLA-B35 upregulates the production of endothelin-1 in HLA-transfected cells: A possible pathogenetic role in pulmonary hypertension

Tissue Antigens

Volumn 68, Issue 3, 2006, Pages 239-244

  Santaniello, A ^a   Salazar, G ^a   Lenna, S ^a   Antonioli, R ^a   Colombo, G ^a   Beretta, L ^a   Scorza, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ECV304; Endothelin 1; HLA class I; HLA B35; Interleukin 1 ; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

ENDOTHELIN 1; HLA B35 ANTIGEN; HLA B8 ANTIGEN; INTERLEUKIN 1BETA; PREPROENDOTHELIN 1;

ALLELE; ARTICLE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ALLELES; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIN-1; HLA-B ANTIGENS; HLA-B35 ANTIGEN; HUMANS; HYPERTENSION, PULMONARY; INTERLEUKIN-1; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; TRANSFECTION; UP-REGULATION;

EID: 33748414062     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00657.x     Document Type: Article

References (26)

1. Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999: 31: 195.
2. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003: 29: 335-49, vii.
3. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001: 40: 453-9.
4. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003: 48: 516-22.
5. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003: 167: 580-6.
6. Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 2004: 34: 442-53.
7. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004: 3: 339-52.
8. Lee SH, Channick RN. Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med 2005: 26: 402-8.
9. La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 1995: 22: 315-23.
10. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001: 2: 90-101.
11. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004: 61: 227-37.
12. Scorza R, Caronni M, Bazzi S et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002: 966: 238-46.
13. Grigolo B, Mazzetti I, Meliconi R et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000: 121: 539-43.
14. Salazar G, Colombo G, Lenna S et al. HLA-B35 influences the apoptosis rate in human peripheral blood mononucleated cells and HLA-transfected cells. Hum Immunol 2006 (in press).
15. Ennis PD, Zemmour J, Salter RD, Parham P. Rapid cloning of HLA-A, B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc Natl Acad Sci U S A 1990: 87: 2833-7.
16. Zemmour J, Little AM, Schendel DJ, Parham P. The HLA-A, B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992: 148: 1941-8.
17. Scorza R. Genetic conditioning and dynamic of viral infections. In: Aiuti F, Bonomo L, Danieli G, eds. Topics in Immunology 1988. Rome: Il Pensiero Scientifico Editore, 1988: 183-202.
18. Yoshizumi M, Kurihara H, Morita T et al. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun 1990: 166: 324-9.
19. Daniel D, Opelz G, Arend M, Canerl S. Induction of apoptosis in human lymphocytes by human anti-HLA class I antibodies. Transplantation 2003: 75: 1380-6.
20. Kawaguchi Y, Suzuki K, Hara M et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994: 53: 506-10.
21. Hussein MR, Hassan HI, Hofny ER et al. Alterations of mononuclear inflammatory cells, CD4/CD81 T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005: 58: 178-84.
22. Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995: 151: 1628-31.
23. Tasaka K, Kitazumi K. The control of endothelin-1 secretion. Gen Pharmacol 1994: 25: 1059-69.
24. Tscherning T, Claesson MH. Signal transduction via MHC class-I molecules in T cells. Scand J Immunol 1994: 39: 117-21.
25. Bian H, Harris PE, Mulder A, Reed EF. Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine I phosphorylation, inositol phosphate generation, and proliferation. Hum Immunol 1997: 53: 90-7.
26. Barst RJ, Loyd JE. Genetics and immunogenetic aspects of primary pulmonary hypertension. Chest 1998: 114: 231-6S.